In November, President Biden set out to change that with a new rule that would drastically expand access to this type of ...

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce ...

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

Semaglutide, the active ingredient in Novo's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving ...

AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading ...

Semaglutide - the powerful ingredient behind Wegovy and Ozempic - has long been hailed a monumental breakthrough in the war ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are ...

Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program.

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...